Founded in 2023, Attovia specializes in treatments for immune-mediated diseases. The company’s core technology, the ATTOBODY platform, is licensed from Alamar Biosciences and utilizes an evolution-based workflow to engineer monospecific, bispecific, and trispecific biologics. This technical foundation has already produced three lead candidates: ATTO-1310, ATTO-2306, and ATTO-1091.

Capital raised through this IPO is earmarked for the clinical progression of these candidates. Dr. Kan Chen, partner at early investor Qiming Venture Partners, noted that the funding provides the necessary momentum to advance the company's research pipeline. Qiming, which has backed more than 580 companies since its 2006 inception, views the listing as a validation of Attovia’s ability to move complex platform technology into clinical-stage development.